Edge Intelligence: The Confluence of Edge Computing and Artificial Intelligence

Shuiguang Deng, Hailiang Zhao, Weijia Fang, +3

IEEE Internet of Things Journal

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

Shukui Qin, Zhenggang Ren, Zhiqiang Meng, +12

The Lancet Oncology

HepatologyMedicinePathologyLiver CancerCancer Treatment +4

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma

Yi Zheng, Tingting Wang, Xiaoxuan Tu, +10

Journal for ImmunoTherapy of Cancer

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle, +200

The Lancet Oncology

OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib +8

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Shukui Qin, Li Qiu, Shanzhi Gu, +31

˜The œLancet. Gastroenterology & hepatology

HepatologyMedicinePathologyLiver CancerCancer Treatment +4

Preoperative Probiotics Decrease Postoperative Infectious Complications of Colorectal Cancer

Jiwei Zhang, Peng Du, Bao-Ren Yang, +3

The American Journal of the Medical Sciences

ProbioticGastroenterologyColorectal CancerSurgeryProbiotics +1

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Shukui Qin, Zhendong Chen, Weijia Fang, +16

Journal of Clinical Oncology

Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC

Xuanwen Bao, Run Shi, Tianyu Zhao, +4

Cancer Immunology Immunotherapy

Tumor BiologySingle Cell SequencingSingle-cell Rna-seqMedicineImmunology +7

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial

Feng Wang, Ying Jin, Min Wang, +22

Nature Medicine

Hdac InhibitorRandomized Phase 2Mss/pmmr Colorectal CancerMedicinePharmacology +6

Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

Feng Wang, Shukui Qin, Xinchen Sun, +14

Journal of Hematology & Oncology

Multicenter Phase 2ImmunologyPathologyImmunotherapeuticsDermatology +19